PHARMACYTE BIOTECH COM USD0.000 (PMCB)

0.0554 -0.0013 ( -2.2065% ) Oct 23

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

PMCB Detailed Quote

Last Trade:   0.0554
Trade Time:   3:59pm
Change:   -0.0013
Perc Change:   -2.2065%
Prev Close:   0.0567
Open:   0.0556
Day's Range:   0.0542 - 0.0599
Bid:   N/A
EPS   -0.0100
52wk Range:   0.0230 - 0.1689
Volume:   3587099
Avg Vol:   1485480
Market Cap:   53.91M
P/E (ttm):   N/A
PES (ttm):   -0.0100
Ask:   N/A

PMCB Recent Headlines

  • PharmaCyte Biotech to Hold Shareholder Call 10/20/2017 01:00 PMPharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L.
  • PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 10/17/2017 01:15 PMPharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado , has identified an organism whose genome contains the genetic code for production of an enzyme capable of activating ...
  • PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 10/10/2017 01:15 PMPharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr.
  • PharmaCyte Biotech Appoints Alan Morell of Creative Management Partners as Strategic Advisor 09/13/2017 12:50 PMPharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Alan Morell, the Chairman and Chief Executive Officer of Creative Management Partners, as a Strategic Advisor to the Chief Executive Officer and Board of ...
  • PharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership 09/06/2017 01:03 PMPharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has reached an agreement with Austrianova to restructure certain agreements between them pursuant to a Binding Term Sheet .

FIND OUT HOW MUCH MOMENTUM IS DRIVING YOUR MARIJUANA STOCK!

AS SEEN ON
>>